^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mezigdomide (CC-92480)

    i
    Other names: CC-92480, BMS-986348, A/I CELMoD, CC 92480, BMS986348, BMS 986348, CC92480
    Company:
    BMS
    Drug class:
    Cereblon modulator
    Related drugs:
    3d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=165, Recruiting, K36 Therapeutics, Inc. | N=125 --> 165
    Enrollment change
    |
    carfilzomib • dexamethasone • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)
    13d
    BELAMI: A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne
    New P2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    28d
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Abdullah Khan | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    29d
    Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways. (PubMed, Blood)
    Mezigdomide treatment in exhausted T cells results in decreased expression of exhaustion-related markers, increased proinflammatory cytokine expression, and enhanced target cell killing with Alnuctamab, a B-cell maturation antigen (BCMA) targeting TCE. This study provides crucial mechanistic insights into the roles of IKZF1/IKZF3 in T cell exhaustion, supporting the rationale for combining mezigdomide with TCEs to enhance therapeutic outcomes in MM.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    alnuctamab (CC-93269) • mezigdomide (CC-92480)
    1m
    Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. (PubMed, Blood)
    Finally, we demonstrate the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy in vivo. Overall, our data show that Mezigdomide treatment improves anti-myeloma T cell therapy efficacy and reduces T cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.
    Journal • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    mezigdomide (CC-92480)
    1m
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    1m
    STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    2ms
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    2ms
    MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Talvey (talquetamab-tgvs) • mezigdomide (CC-92480)
    2ms
    24CH294: A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies - The IFM 2024-01 clinical trial (BELAMI) (2025-520976-25-00)
    P1/2, N=44, Not yet recruiting, Centre Hospitalier Universitaire De Saint Etienne
    New P1/2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    2ms
    A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (2025-521090-14-00)
    P1/2, N=70, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1/2 trial
    |
    carfilzomib • dexamethasone • mezigdomide (CC-92480)
    2ms
    Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Abecma (idecabtagene vicleucel) • mezigdomide (CC-92480)